Stable or Increasing Bone Mineral Density in HIV-infected Patients Treated with Nelfinavir or Indinavir
Overview
Affiliations
Background And Objectives: To determine the factors contributing to changes in bone mineral density (BMD) over time in HIV-infected patients receiving highly active antiretroviral therapy (HAART).
Methods: Analyses of lumbar spine BMD in 183 male Caucasian participants in the Western Australian HIV Cohort study, comprising a longitudinal analysis of data from 54 patients on stable HAART regimens, and a cross-sectional analysis comparing data from 131 protease inhibitor (PI)-treated patients and 52 PI-naive (including 28 antiretroviral treatment-naive) patients.
Results: Average lumbar spine BMD remained stable or increased over the time frame considered. Although there was no evidence of a change of average BMD over time in patients receiving nelfinavir (P = 0.92), there was evidence of increasing bone density in the indinavir group (average increase, 0.31 z-score per year; P < 0.001). Lower initial z-scores in the longitudinal analysis were significantly associated with lower pre-HAART BMI (P = 0.003), consistent with results of the cross-sectional analysis in which lowest BMI prior to initial dual X-ray absorptiometry scan was associated with decreased BMD (P = 0.02, overall group). Although PI therapy was also associated with decreased BMD in a univariate analysis of the cross-sectional data (P = 0.04), this effect was abrogated in a multiple linear regression analysis (P = 0.11) with lowest BMI remaining significant (P = 0.04).
Conclusions: We found no evidence, overall, of accelerated bone loss in patients treated with nelfinavir- or indinavir-containing HAART regimens, and propose that indinavir therapy may be associated with an increase in bone mineral density over time. Pre-HAART BMI was an independent and powerful determinant of an individual's initial z-score in the longitudinal analysis, and adjustment for this effect in a cross-sectional analysis abrogated the association between PI therapy and decreased lumbar spine z-score.
Mwaka E, Munabi I, Castelnuovo B, Kaimal A, Kasozi W, Kambugu A PLoS One. 2021; 16(2):e0246389.
PMID: 33544754 PMC: 7864439. DOI: 10.1371/journal.pone.0246389.
Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis.
Delpino M, Quarleri J Front Endocrinol (Lausanne). 2020; 11:502.
PMID: 32982960 PMC: 7493215. DOI: 10.3389/fendo.2020.00502.
Bone methabolic disorders in HIV positive patients: a case report.
De Carli A, Gaj E, Desideri D, Scrivano M, Fedeli G, Pasquale Vadala A Acta Biomed. 2020; 91(3):e2020081.
PMID: 32921777 PMC: 7716982. DOI: 10.23750/abm.v91i3.9026.
Costa C, Scabini S, Kaimal A, Kasozi W, Cusato J, Kafufu B J Infect Dis. 2020; 222(2):263-272.
PMID: 32112093 PMC: 7323491. DOI: 10.1093/infdis/jiaa088.
Puthanakit T, Wittawatmongkol O, Poomlek V, Sudjaritruk T, Brukesawan C, Bunupuradah T J Virus Erad. 2018; 4(1):6-11.
PMID: 29568546 PMC: 5851189.